Journal Club: Anti‐CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus

OBJECTIVE: Despite substantial advances in the treatment of systemic lupus erythematosus (SLE), some patients do not respond to the current state‐of‐the art therapies. This study assessed the tolerability and efficacy of CD19 chimeric antigen receptor (CAR) T cells in a small series of seriously ill...

Descripción completa

Detalles Bibliográficos
Autores principales: Boulougoura, Afroditi, Gendelman, Hannah, Surmachevska, Natalya, Kyttaris, Vasileios C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2023
Materias:
Journal Club
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642250/
https://www.ncbi.nlm.nih.gov/pubmed/37766597
http://dx.doi.org/10.1002/acr2.11614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642250/
https://www.ncbi.nlm.nih.gov/pubmed/37766597
http://dx.doi.org/10.1002/acr2.11614

Ejemplares similares